PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE PRESCRIBERS, 6TH EDITION BY TERI
MOSER TEST BANK – PRACTICE QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains
Pharmacokinetics and Pharmacodynamics
Prescribing for Special Populations
Cardiovascular Pharmacology
Anti-Infective Agents
Neurological and Psychiatric Medications
Endocrine System Management
Respiratory Therapeutics
Professional, Legal, and Ethical Prescribing
Introduction
This comprehensive assessment is designed to evaluate the clinical proficiency and decision-making capabilities
of advanced practice nursing students and practitioners. The exam covers essential pharmacotherapeutic
principles, including drug selection, monitoring, and patient education across the lifespan. By utilizing both
foundational multiple-choice questions and complex clinical scenarios, this test bank simulates real-world
challenges encountered in primary and acute care settings. Candidates are assessed on their ability to integrate
physiological principles with pharmacological interventions while adhering to legal and ethical standards of
practice. The focus remains on evidence-based prescribing to ensure safe, effective, and patient-centered
outcomes in various therapeutic domains.
SECTION ONE: QUESTIONS 1–100
, 1. Which of the following factors primarily influences the bioavailability of an orally administered drug?
A. Plasma protein binding
B. Renal clearance rate
C. First-pass hepatic metabolism
D. Volume of distribution
🟢 C. First-pass hepatic metabolism
🔴 RATIONALE: Bioavailability refers to the fraction of the drug that reaches systemic circulation. Drugs absorbed
from the GI tract pass through the liver via the portal vein; significant metabolism here reduces the amount of
active drug available to the body.
2. An 82-year-old patient is prescribed a new medication. The nurse prescriber understands that which age-
related change most significantly impacts drug clearance?
A. Increased gastric pH
B. Decreased glomerular filtration rate
C. Increased body fat percentage
D. Decreased serum albumin
🟢 B. Decreased glomerular filtration rate
🔴 RATIONALE: Renal function typically declines with age. Since many drugs are excreted via the kidneys, a
reduced GFR increases the half-life of drugs and heightens the risk of toxicity, making it the most critical factor for
clearance.
3. When prescribing a prodrug, the clinician must be aware that the drug:
,A. Is active upon administration
B. Requires metabolic conversion to become active
C. Bypasses the liver entirely
D. Is excreted unchanged by the kidneys
🟢 B. Requires metabolic conversion to become active
🔴 RATIONALE: A prodrug is pharmacologically inactive when administered and must be metabolized (usually by
the liver) into its active form to exert therapeutic effects.
4. A patient is taking Warfarin and is now prescribed Amiodarone. What is the expected interaction?
A. Amiodarone induces metabolism, decreasing Warfarin levels
B. Amiodarone inhibits metabolism, increasing Warfarin levels
C. Amiodarone decreases Warfarin absorption in the gut
D. There is no known interaction between these drugs
🟢 B. Amiodarone inhibits metabolism, increasing Warfarin levels
🔴 RATIONALE: Amiodarone is a potent CYP450 inhibitor. It slows the metabolism of Warfarin, leading to
increased plasma concentrations and a higher risk of bleeding, requiring a Warfarin dose reduction.
5. Which schedule of controlled substances has the highest potential for abuse while still having an accepted
medical use?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule IV
, 🟢 B. Schedule II
🔴 RATIONALE: Schedule II drugs (e.g., morphine, oxycodone) have a high potential for abuse and severe
physical or psychological dependence but are legally used in medical practice. Schedule I drugs have no
accepted medical use.
6. A patient with Stage 4 Chronic Kidney Disease requires an antibiotic. Which adjustment is most
appropriate?
A. Increasing the loading dose
B. Shortening the dosing interval
C. Reducing the dose or lengthening the interval
D. Switching to an herbal supplement
🟢 C. Reducing the dose or lengthening the interval
🔴 RATIONALE: To prevent drug accumulation and toxicity in patients with impaired renal function, the clinician
must either decrease the individual dose or increase the time between doses based on creatinine clearance.
7. What is the primary goal of the "steady state" in pharmacotherapeutics?
A. To ensure the drug is eliminated completely before the next dose
B. To maintain a therapeutic concentration of the drug in the plasma
C. To prevent any side effects from occurring
D. To reach the peak concentration within one hour of administration
🟢 B. To maintain a therapeutic concentration of the drug in the plasma
🔴 RATIONALE: Steady state is achieved when the rate of drug administration equals the rate of drug elimination,
typically occurring after 4 to 5 half-lives, ensuring consistent therapeutic levels.
MOSER TEST BANK – PRACTICE QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS
RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains
Pharmacokinetics and Pharmacodynamics
Prescribing for Special Populations
Cardiovascular Pharmacology
Anti-Infective Agents
Neurological and Psychiatric Medications
Endocrine System Management
Respiratory Therapeutics
Professional, Legal, and Ethical Prescribing
Introduction
This comprehensive assessment is designed to evaluate the clinical proficiency and decision-making capabilities
of advanced practice nursing students and practitioners. The exam covers essential pharmacotherapeutic
principles, including drug selection, monitoring, and patient education across the lifespan. By utilizing both
foundational multiple-choice questions and complex clinical scenarios, this test bank simulates real-world
challenges encountered in primary and acute care settings. Candidates are assessed on their ability to integrate
physiological principles with pharmacological interventions while adhering to legal and ethical standards of
practice. The focus remains on evidence-based prescribing to ensure safe, effective, and patient-centered
outcomes in various therapeutic domains.
SECTION ONE: QUESTIONS 1–100
, 1. Which of the following factors primarily influences the bioavailability of an orally administered drug?
A. Plasma protein binding
B. Renal clearance rate
C. First-pass hepatic metabolism
D. Volume of distribution
🟢 C. First-pass hepatic metabolism
🔴 RATIONALE: Bioavailability refers to the fraction of the drug that reaches systemic circulation. Drugs absorbed
from the GI tract pass through the liver via the portal vein; significant metabolism here reduces the amount of
active drug available to the body.
2. An 82-year-old patient is prescribed a new medication. The nurse prescriber understands that which age-
related change most significantly impacts drug clearance?
A. Increased gastric pH
B. Decreased glomerular filtration rate
C. Increased body fat percentage
D. Decreased serum albumin
🟢 B. Decreased glomerular filtration rate
🔴 RATIONALE: Renal function typically declines with age. Since many drugs are excreted via the kidneys, a
reduced GFR increases the half-life of drugs and heightens the risk of toxicity, making it the most critical factor for
clearance.
3. When prescribing a prodrug, the clinician must be aware that the drug:
,A. Is active upon administration
B. Requires metabolic conversion to become active
C. Bypasses the liver entirely
D. Is excreted unchanged by the kidneys
🟢 B. Requires metabolic conversion to become active
🔴 RATIONALE: A prodrug is pharmacologically inactive when administered and must be metabolized (usually by
the liver) into its active form to exert therapeutic effects.
4. A patient is taking Warfarin and is now prescribed Amiodarone. What is the expected interaction?
A. Amiodarone induces metabolism, decreasing Warfarin levels
B. Amiodarone inhibits metabolism, increasing Warfarin levels
C. Amiodarone decreases Warfarin absorption in the gut
D. There is no known interaction between these drugs
🟢 B. Amiodarone inhibits metabolism, increasing Warfarin levels
🔴 RATIONALE: Amiodarone is a potent CYP450 inhibitor. It slows the metabolism of Warfarin, leading to
increased plasma concentrations and a higher risk of bleeding, requiring a Warfarin dose reduction.
5. Which schedule of controlled substances has the highest potential for abuse while still having an accepted
medical use?
A. Schedule I
B. Schedule II
C. Schedule III
D. Schedule IV
, 🟢 B. Schedule II
🔴 RATIONALE: Schedule II drugs (e.g., morphine, oxycodone) have a high potential for abuse and severe
physical or psychological dependence but are legally used in medical practice. Schedule I drugs have no
accepted medical use.
6. A patient with Stage 4 Chronic Kidney Disease requires an antibiotic. Which adjustment is most
appropriate?
A. Increasing the loading dose
B. Shortening the dosing interval
C. Reducing the dose or lengthening the interval
D. Switching to an herbal supplement
🟢 C. Reducing the dose or lengthening the interval
🔴 RATIONALE: To prevent drug accumulation and toxicity in patients with impaired renal function, the clinician
must either decrease the individual dose or increase the time between doses based on creatinine clearance.
7. What is the primary goal of the "steady state" in pharmacotherapeutics?
A. To ensure the drug is eliminated completely before the next dose
B. To maintain a therapeutic concentration of the drug in the plasma
C. To prevent any side effects from occurring
D. To reach the peak concentration within one hour of administration
🟢 B. To maintain a therapeutic concentration of the drug in the plasma
🔴 RATIONALE: Steady state is achieved when the rate of drug administration equals the rate of drug elimination,
typically occurring after 4 to 5 half-lives, ensuring consistent therapeutic levels.
